A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
Clinical trial NCT01603979 · COMPLETED
Trial details
- NCT number
- NCT01603979
- Sponsor
- AVEO Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-05-01
- Primary completion
- 2014-12-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.